The DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Therapeutic strategies for human amyloid diseases
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Metabolic Basis of Inherited Disease.
(1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-503_7 · Cited by 7,786
The Metabolic Basis of Inherited Disease
(1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-5-389_2 · Cited by 3,983
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Protein misfolding, evolution and disease
Dobson, C. M. (1999) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(99)01445-0 · Cited by 1,952
Common core structure of amyloid fibrils by synchrotron X-ray diffraction 1 1Edited by F. E. Cohen
Sunde, M., Serpell, L. C., Bartlam, M., Fraser, P. E., Pepys, M. B., & Blake, C. C. F. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.1348 · Cited by 1,707
Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
Morgan, D., Diamond, D. M., Gottschall, P. E., Ugen, K. E., Dickey, C., Hardy, J., Duff, K., Jantzen, P., DiCarlo, G., Wilcock, D., et al. (2000) · Nature · doi:10.1038/35050116 · Cited by 1,498
Production of the Alzheimer Amyloid β Protein by Normal Proteolytic Processing
Shoji, M., Golde, T. E., Ghiso, J., Cheung, T. T., Estus, S., Shaffer, L. M., Cai, X.-D., McKay, D. M., Tintner, R., Frangione, B., et al. (1992) · Science · doi:10.1126/science.1439760 · Cited by 1,447
A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., et al. (2001) · Nature · doi:10.1038/35102591 · Cited by 1,388 · cited 1×
“cgi?l=23621">β-secretase inhibitors are now available as potential therapeutics to prevent the processing of APP into the amyloid-β peptide — the 39–43-residue peptide that assembles into Alzheimer's fibril”
BackgroundAggregation and Motor Neuron Toxicity of an ALS-Linked SOD1 Mutant Independent from Wild-Type SOD1
Bruijn, L. I., Houseweart, M. K., Kato, S., Anderson, K. L., Anderson, S. D., Ohama, E., Reaume, A. G., Scott, R. W., & Cleveland, D. W. (1998) · Science · doi:10.1126/science.281.5384.1851 · Cited by 1,228
Protein aggregation: folding aggregates, inclusion bodies and amyloid
Fink, A. L. (1998) · Folding and Design · doi:10.1016/s1359-0278(98)00002-9 · Cited by 1,157
Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis
Booth, D. R., Sunde, M., Bellotti, V., Robinson, C. V., Hutchinson, W. L., Fraser, P. E., Hawkins, P. N., Dobson, C. M., Radford, S. E., Blake, C. C. F., et al. (1997) · Nature · doi:10.1038/385787a0 · Cited by 1,048
Designing conditions for in vitro formation of amyloid protofilaments and fibrils
Chiti, F., Webster, P., Taddei, N., Clark, A., Stefani, M., Ramponi, G., & Dobson, C. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3590 · Cited by 1,039
Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum?
Klein, W. (2001) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01749-5 · Cited by 989
Alzheimer's Disease--Genotypes, Phenotype, and Treatments
Selkoe, D. J. (1997) · Science · doi:10.1126/science.275.5300.630 · Cited by 875
Amyloid β-Protein and the Genetics of Alzheimer's Disease
Selkoe, D. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.31.18295 · Cited by 799
Conway, K. A., Harper, J. D., & Lansbury, P. T. (2000) · Biochemistry · doi:10.1021/bi991447r · Cited by 786
Processing of the Amyloid Protein Precursor to Potentially Amyloidogenic Derivatives
Golde, T. E., Estus, S., Younkin, L. H., Selkoe, D. J., & Younkin, S. G. (1992) · Science · doi:10.1126/science.1738847 · Cited by 737
Scherzinger, E., Sittler, A., Schweiger, K., Heiser, V., Lurz, R., Hasenbank, R., Bates, G. P., Lehrach, H., & Wanker, E. E. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4604 · Cited by 705
Fibril in senile systemic amyloidosis is derived from normal transthyretin.
Westermark, P., Sletten, K., Johansson, B., & Cornwell, G. G. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.7.2843 · Cited by 696
Kirkitadze, M. D., Condron, M. M., & Teplow, D. B. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.4970 · Cited by 682
Volles, M. J., Lee, S.-J., Rochet, J.-C., Shtilerman, M. D., Ding, T. T., Kessler, J. C., & Lansbury, P. T. (2001) · Biochemistry · doi:10.1021/bi0102398 · Cited by 682
Human lysozyme gene mutations cause hereditary systemic amyloidosis
Pepys, M. B., Hawkins, P. N., Booth, D. R., Vigushin, D. M., Tennent, G. A., Soutar, A. K., Totty, N., Nguyen, O., Blake, C. C. F., Terry, C. J., et al. (1993) · Nature · doi:10.1038/362553a0 · Cited by 657
Fan, J.-Q., Ishii, S., Asano, N., & Suzuki, Y. (1999) · Nature Medicine · doi:10.1038/4801 · Cited by 614
Alternative conformations of amyloidogenic proteins govern their behavior
Kelly, J. W. (1996) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(96)80089-3 · Cited by 593
Self-citationLai, Z., Colón, W., & Kelly, J. W. (1996) · Biochemistry · doi:10.1021/bi952501g · Cited by 574
Self-citationPartial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro
Colon, W., & Kelly, J. W. (1992) · Biochemistry · doi:10.1021/bi00151a036 · Cited by 573
Self-citationAntibodies inhibit prion propagation and clear cell cultures of prion infectivity
Peretz, D., Williamson, R. A., Kaneko, K., Vergara, J., Leclerc, E., Schmitt-Ulms, G., Mehlhorn, I. R., Legname, G., Wormald, M. R., Rudd, P. M., et al. (2001) · Nature · doi:10.1038/35089090 · Cited by 525
Cryo-electron microscopy structure of an SH3 amyloid fibril and model of the molecular packing
Jiménez, J. L., Guijarro, J. I., Orlova, E., Zurdo, J., Dobson, C. M., Sunde, M., & Saibil, H. R. (1999) · The EMBO Journal · doi:10.1093/emboj/18.4.815 · Cited by 503
Is there a cause-and-effect relationship between α-synuclein fibrillization and Parkinson’s disease?
Goldberg, M. S., & Lansbury Jr, P. T. (2000) · Nature Cell Biology · doi:10.1038/35017124 · Cited by 458
Saraiva, M. J., Birken, S., Costa, P. P., & Goodman, D. S. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111390 · Cited by 434
Krebs, M. R. H., Wilkins, D. K., Chung, E. W., Pitkeathly, M. C., Chamberlain, A. K., Zurdo, J., Robinson, C. V., & Dobson, C. M. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.3862 · Cited by 412
Rational design of potent human transthyretin amyloid disease inhibitors.
Sacchettini, J. C., Klabunde, T., Petrassi, H. M., Oza, V. B., Raman, P., & Kelly, J. W. (2000) · Nature Structural Biology · doi:10.1038/74082 · Cited by 379
Self-citationCreation of "Amyloid" Fibrils from Bence Jones Proteins in vitro
Glenner, G. G., Ein, D., Eanes, E. D., Bladen, H. A., Terry, W., & Page, D. L. (1971) · Science · doi:10.1126/science.174.4010.712 · Cited by 377
Blake, C., & Serpell, L. (1996) · Structure · doi:10.1016/s0969-2126(96)00104-9 · Cited by 376
Kisilevsky, R., Lemieux, L. J., Fraser, P. E., Kong, X., Hultin, P. G., & Szarek, W. A. (1995) · Nature Medicine · doi:10.1038/nm0295-143 · Cited by 363
Sipe, J. D. (1992) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.61.070192.004503 · Cited by 352
A role for destabilizing amino acid replacements in light-chain amyloidosis.
Hurle, M. R., Helms, L. R., Li, L., Chan, W., & Wetzel, R. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.12.5446 · Cited by 348
Inhibiting transthyretin amyloid fibril formation via protein stabilization
Miroy, G. J., Lai, Z., Lashuel, H. A., Peterson, S. A., Strang, C., & Kelly, J. W. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.26.15051 · Cited by 344
Self-citationThe protofilament substructure of amyloid fibrils11Edited by F. E. Cohen
Serpell, L. C., Sunde, M., Benson, M. D., Tennent, G. A., Pepys, M. B., & Fraser, P. E. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.3908 · Cited by 342
APOE genotype predicts when — not whether — one is predisposed to develop Alzheimer disease
Meyer, M. R., Tschanz, J. T., Norton, M. C., Welsh-Bohmer, K. A., Steffens, D. C., Wyse, B. W., & Breitner, J. C. S. (1998) · Nature Genetics · doi:10.1038/1206 · Cited by 334
Khurana, R., Gillespie, J. R., Talapatra, A., Minert, L. J., Ionescu-Zanetti, C., Millett, I., & Fink, A. L. (2001) · Biochemistry · doi:10.1021/bi001782b · Cited by 325
Trans -Suppression of Misfolding in an Amyloid Disease
Hammarström, P., Schneider, F., & Kelly, J. W. (2001) · Science · doi:10.1126/science.1062245 · Cited by 293
Self-citationMutations and off-pathway aggregation of proteins
Wetzel, R. (1994) · Trends in Biotechnology · doi:10.1016/0167-7799(94)90082-5 · Cited by 262
Kimberly, W. T., Xia, W., Rahmati, T., Wolfe, M. S., & Selkoe, D. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.5.3173 · Cited by 253
An Engineered Transthyretin Monomer that Is Nonamyloidogenic, Unless It Is Partially Denatured
Jiang, X., Smith, C. S., Petrassi, H. M., Hammarström, P., White, J. T., Sacchettini, J. C., & Kelly, J. W. (2001) · Biochemistry · doi:10.1021/bi011194d · Cited by 239
Self-citationLashuel, H. A., Lai, Z., & Kelly, J. W. (1998) · Biochemistry · doi:10.1021/bi981876+ · Cited by 206
Self-citationInhibiting transthyretin conformational changes that lead to amyloid fibril formation
Peterson, S. A., Klabunde, T., Lashuel, H. A., Purkey, H., Sacchettini, J. C., & Kelly, J. W. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.12956 · Cited by 206
Self-citationKelly, J. W. (1997) · Structure · doi:10.1016/s0969-2126(97)00215-3 · Cited by 205
Self-citationTransthyretin Quaternary and Tertiary Structural Changes Facilitate Misassembly into Amyloid
KELLY, J., COLON, W., LAI, Z., LASHUEL, H., MCCULLOCH, J., MCCUTCHEN, S., MIROY, G., & PETERSON, S. (1997) · Advances in Protein Chemistry · doi:10.1016/s0065-3233(08)60321-6 · Cited by 204
Self-citationComparison of Lethal and Nonlethal Transthyretin Variants and Their Relationship to Amyloid Disease
McCutchen, S. L., Lai, Z., Miroy, G. J., Kelly, J. W., & Colon, W. (1995) · Biochemistry · doi:10.1021/bi00041a032 · Cited by 198
Self-citationMimicking dominant negative inhibition of prion replication through structure-based drug design
Perrier, V., Wallace, A. C., Kaneko, K., Safar, J., Prusiner, S. B., & Cohen, F. E. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.11.6073 · Cited by 181
Intralysosomal formation of amyloid fibrils.
Shirahama, T., & Cohen, A. S. (1975) · PubMed · Cited by 167
Jiang, X., Buxbaum, J. N., & Kelly, J. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.261419998 · Cited by 166
Self-citationSipe, J. D., & Cohen, A. S. (1994) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408369409084679 · Cited by 165
The Heparin/Heparan Sulfate-binding Site on Apo-serum Amyloid A
Ancsin, J. B., & Kisilevsky, R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.11.7172 · Cited by 158
Furin mediates enhanced production of fibrillogenic ABri peptides in familial British dementia
Kim, S.-H., Wang, R., Gordon, D. J., Bass, J., Steiner, D. F., Lynn, D. G., Thinakaran, G., Meredith, S. C., & Sisodia, S. S. (1999) · Nature Neuroscience · doi:10.1038/14783 · Cited by 154
Protein Aggregation and Pathogenesis of Huntingtons Disease: Mechanisms and Correlations
Wanker, E. E. (2000) · Biological Chemistry · doi:10.1515/bc.2000.114 · Cited by 154
Serpell, L. C., Sunde, M., Fraser, P. E., Luther, P. K., Morris, E. P., Sangren, O., Lundgren, E., & Blake, C. C. F. (1995) · Journal of Molecular Biology · doi:10.1006/jmbi.1995.0604 · Cited by 144
Furin initiates gelsolin familial amyloidosis in the Golgi through a defect in Ca2+ stabilization
Chen, C.-D., Huff, M. E., Matteson, J., Page, L. J., Phillips, R., Kelly, J. W., & Balch, W. E. (2001) · The EMBO Journal · doi:10.1093/emboj/20.22.6277 · Cited by 141
Self-citationDiscovering transthyretin amyloid fibril inhibitors by limited screening
Baures, P. W., Peterson, S., & Kelly, J. W. (1998) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(98)00130-8 · Cited by 141
Self-citationA glimpse of a possible amyloidogenic intermediate of transthyretin.
Wemmer, D. E., Liu, K., Cho, H. S., et al. (2000) · Nature Structural Biology · doi:10.1038/78980 · Cited by 138
Yamazaki, T., Koo, E. H., & Selkoe, D. J. (1996) · Journal of Cell Science · doi:10.1242/jcs.109.5.999 · Cited by 138
Baures, P. W., Oza, V. B., Peterson, S., & Kelly, J. W. (1999) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(99)00066-8 · Cited by 135
Self-citationOza, V. B., Smith, C., Raman, P., Koepf, E. K., Lashuel, H. A., Petrassi, H. M., Chiang, K. P., Powers, E. T., Sachettinni, J., & Kelly, J. W. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010257n · Cited by 133
Self-citationKelly, J. W., & Lansbury, P. T. (1994) · Amyloid · doi:10.3109/13506129409148451 · Cited by 127
Self-citationFamilial amyloidotic polyneuropathy
Benson, M. D., & Roudebush, R. L. (1989) · Trends in Neurosciences · doi:10.1016/0166-2236(89)90162-8 · Cited by 125
Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma
Purkey, H. E., Dorrell, M. I., & Kelly, J. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091431798 · Cited by 124
Self-citation(1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-110-6-499_4 · Cited by 115
The environmental dependency of protein folding best explains prion and amyloid diseases
Kelly, J. W. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.3.930 · Cited by 113
Self-citationYang, A. J., Chandswangbhuvana, D., Shu, T., Henschen, A., & Glabe, C. G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.29.20650 · Cited by 108
APOE is a major susceptibility gene for Alzheimer’s disease
Roses, A. D., & Saunders, A. M. (1994) · Current Opinion in Biotechnology · doi:10.1016/0958-1669(94)90091-4 · Cited by 108
Amyloid enhancing factor-loaded macrophages in amyloid fibril formation.
Shirahama, T., Miura, K., Ju, S., Kisilevsky, R., Gruys, E., & Cohen, A. S. (1990) · PubMed · Cited by 105
White, J. T., & Kelly, J. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.241406698 · Cited by 86
Self-citationStructure-Based Design of N-Phenyl Phenoxazine Transthyretin Amyloid Fibril Inhibitors
Petrassi, H. M., Klabunde, T., Sacchettini, J. C., & Kelly, J. W. (2000) · Journal of the American Chemical Society · doi:10.1021/ja993309v · Cited by 84
Self-citationAmyloidosis: a familiar problem in the light of current pathogenetic developments.
Kisilevsky, R. (1983) · PubMed · Cited by 83
Genetic Aspects of Amyloidosis
Jacobson, D. R., & Buxbaum, J. N. (1991) · Springer eBooks · doi:10.1007/978-1-4684-5958-6_2 · Cited by 82
Koepf, E. K., Petrassi, H. M., Ratnaswamy, G., Huff, M. E., Sudol, M., & Kelly, J. W. (1999) · Biochemistry · doi:10.1021/bi991105l · Cited by 80
Self-citationSuhr, O. B., Hietala, S.-O., Riklund, K., Pepys, M. B., Hawkins, P. N., & Rydh, A. (1998) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050273 · Cited by 80
Synthesis and evaluation of anthranilic acid-based transthyretin amyloid fibril inhibitors
Oza, V. B., Petrassi, H. M., Purkey, H. E., & Kelly, J. W. (1999) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00696-9 · Cited by 78
Self-citationHammarström, P., Jiang, X., Deechongkit, S., et al. (2001) · Biochemistry · doi:10.1021/bi010673+ · Cited by 75
Transmissible spongiform encephalopathies, amyloidoses and yeast prions: Common threads?
Caughey, B. W. (2000) · Nature Medicine · doi:10.1038/77476 · Cited by 71
Coelho, T., Chorão, R., Sousa, A., Alves, I. L., Torres, M. F., & Saraiva, M. J. (1996) · Neuromuscular Disorders · doi:10.1016/0960-8966(96)88826-2 · Cited by 61
Wei, Y., McLendon, G. L., Case, M. A., Purring-Koch, C., Yu, T., Hamilton, A. D., Lin, Q., Park, H. S., & Lee, C.-S. (2001) · Chemical Communications · doi:10.1039/b104142h · Cited by 58
Bohrmann, B., Adrian, M., Dubochet, J., Kuner, P., Müller, F., Huber, W., Nordstedt, C., & Döbeli, H. (2000) · Journal of Structural Biology · doi:10.1006/jsbi.2000.4241 · Cited by 58
Protein aggregation in Huntington’s and Parkinson’s disease: implications for therapy
Wanker, E. E. (2000) · Molecular Medicine Today · doi:10.1016/s1357-4310(00)01761-5 · Cited by 54
Does citrate transport supply both acetyl groups and NADPH for cytoplasmic fatty acid synthesis?
Conover, T. E. (1987) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(87)90042-9 · Cited by 53
[29] Screening for pharmacologic inhibitors of amyloid fibril formation
LeVine, H., & Scholten, J. D. (1999) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(99)09031-x · Cited by 43
Aβ immunization: Moving Aβ peptide from brain to blood
Lee, V. M. ‐. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171311798 · Cited by 23
[30] Design and testing of inhibitors of fibril formation
Findeis, M. A., & Molineaux, S. M. (1999) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(99)09032-1 · Cited by 21
Inhibitors of Aβ Peptide Aggregation as Potential Anti-Aizheimer Agents
Bandiera, T., Lansen, J., Post, C., & Varasi, M. (1997) · Current Medicinal Chemistry · doi:10.2174/0929867304666220313105818 · Cited by 21
Prion protein amyloid and neurodegeneration
Prusiner, S. B., & DeArmond, S. J. (1995) · Amyloid · doi:10.3109/13506129509031887 · Cited by 20
Inhibition of β-amyloid formation as a therapeutic strategy
Moore, C. L., & Wolfe, M. S. (1999) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.9.2.135 · Cited by 19
Moyer, B. D., & Balch, W. E. (2001) · Emerging Therapeutic Targets · doi:10.1517/14728222.5.2.165 · Cited by 9
A beta oligomerization A Therapeutic Target for Alzheimers Disease
Howlett, D. R. (2001) · Current Medicinal Chemistry - Immunology Endocrine & Metabolic Agents · doi:10.2174/1568013013359140 · Cited by 4
Cited by
Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease
Sampson, T. R., Debelius, J. W., Thron, T., Janssen, S., Shastri, G. G., Ilhan, Z. E., Challis, C., Schretter, C. E., Rocha, S., Gradinaru, V., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.018 · Cited by 3,622
Protein aggregation and neurodegenerative disease
Ross, C. A., & Poirier, M. A. (2004) · Nature Medicine · doi:10.1038/nm1066 · Cited by 3,454
Unfolding the role of protein misfolding in neurodegenerative diseases
Soto, C. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1007 · Cited by 1,506
EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers
Ehrnhoefer, D. E., Bieschke, J., Boeddrich, A., Herbst, M., Masino, L., Lurz, R., Engemann, S., Pastore, A., & Wanker, E. E. (2008) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1437 · Cited by 1,434
Therapeutic approaches to protein-misfolding diseases
Cohen, F. E., & Kelly, J. W. (2003) · Nature · doi:10.1038/nature02265 · Cited by 800
Self-citation
Metadata
- Authors
- Sacchettini, J. C., & Kelly, J. W.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2002-04
- Volume
- 1
- Issue
- 4
- Pages
- 267-275
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2044788929
- Cited by
- 261
- References
- 95
- FWCI
- 1.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.